COCPCocrystal Pharma, Inc.vs its industry peers
A metric-by-metric comparison of Cocrystal Pharma, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COCPThis | $19M#4 | — | 18.5x#6 | 9.6x#3 | -69.3%#4 | 49.5%#2 | -447.8%#3 | -845.9%#6 | -20.4%#2 | 3#3 | -10.7%#3 | — |
| ATOS | $24M#1 | — | 0.9x#4 | 13623.6x#6 | -95.6%#5 | -36.3%#6 | -2112684.9%#6 | -129.6%#5 | — | — | -82.0%#5 | — |
| AYTU | $21M#2 | — | 0.6x#2 | 0.4x#1 | -13.3%#3 | -5.1%#4 | -14.4%#1 | -40.5%#2 | -43.8%#3 | 4#2 | -10.5%#2 | — |
| TXMD | $21M#3 | — | 0.8x#3 | 6.9x#2 | 71.6%#1 | 73.9%#1 | -145.3%#2 | -2.1%#1 | -3.8%#1 | 5#1 | 50.0%#1 | — |
| ELAB | $18M#5 | — | 1.1x#5 | 29.9x#4 | — | -24.0%#5 | -1304.4%#4 | -46.3%#3 | — | — | -99.8%#6 | — |
| CTXR | $15M#6 | — | 0.2x#1 | 169.7x#5 | 0.0%#2 | -0.8%#3 | -42806.2%#5 | -59.7%#4 | — | — | -64.3%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice